SABR-ATAC: A Trial of TGF-beta Inhibition and Stereotactic Ablative Radiotherapy for Early Stage Non-small Cell Lung Cancer

NCT02581787 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Stage IA Non-Small Cell Lung Carcinoma
Stage IB Non-Small Cell Lung Carcinoma

Interventions

BIOLOGICAL: Fresolimumab
RADIATION: Stereotactic Body Radiation Therapy

Sponsor

Maximilian Diehn

Collaborators

[object Object]